Active, not recruitingNot applicableNCT01817192
Adjuvant Chemotherapy in Patients With Intermediate or High Risk Stage I or Stage IIA Non-squamous Non-Small Cell Lung Cancer: AIM-HIGH (Adjuvant Intervention in Molecular High Risk Patients)
Studying NON RARE IN EUROPE: Non-small cell lung cancer
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Razor Genomics
- Principal Investigator
- David R Spigel, MDSarah Cannon, The Cancer Institute of HCA Healthcare
- Intervention
- Adjuvant Chemotherapy(drug)
- Enrollment
- 420 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2020 – 2027
Study locations (30)
- Leonard Cancer Institute, Mission Viejo, California, United States
- UC Davis Comprehensive Cancer Center, Sacramento, California, United States
- Providence Medical Foundation Santa Rosa, Santa Rosa, California, United States
- Sarah Cannon- FCS South, Fort Meyers, Florida, United States
- Sarah Cannon- FCS North, Petersburg, Florida, United States
- Sarah Cannon- FCS Panhandle, Tallahassee, Florida, United States
- Sarah Cannon- FCS East, West Palm Beach, Florida, United States
- Baptist Health Lexington, Lexington, Kentucky, United States
- Baptist Health Louisville, Louisville, Kentucky, United States
- Mercy Hospital Joplin Missouri, Joplin, Missouri, United States
- Mercy Oncology Research St. Louis, St Louis, Missouri, United States
- Hackensack Meridian Health, Neptune City, New Jersey, United States
- Sarah Cannon- Messino Cancer Center, Asheville, North Carolina, United States
- Mercy Oncology Research Oklahoma City, Oklahoma City, Oklahoma, United States
- Allegheny Health Network Research Institute, Pittsburgh, Pennsylvania, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
Encore Clinical
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01817192 on ClinicalTrials.govOther trials for NON RARE IN EUROPE: Non-small cell lung cancer
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07224152NBTXR3 With Radiation Therapy Alone for Locally-advanced Non-small Cell Lung CancerM.D. Anderson Cancer Center
- ACTIVE NOT RECRUITINGPHASE2, PHASE3NCT05987956Pharmacogenomics IND EXEMPT SNP Clinical Trial - Alectinib and Single Nucleotide PolymorphismsHan Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
- RECRUITINGPHASE2NCT07104630Pulmonary Rehabilitation in Advanced Lung Cancer SurvivorsCase Comprehensive Cancer Center
- RECRUITINGPHASE2NCT06878274Post-operative Radiotherapy After Neodjuvant Chemo-immunotherapy and Surgery in Stage III NSCLCCentre hospitalier de l'Université de Montréal (CHUM)
- RECRUITINGEARLY PHASE1NCT07274813A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX37 in Advanced/Metastatic Solid TumorsShanghai Henlius Biotech
- RECRUITINGPHASE1NCT07358806Study to Assess the Effect of OCT-598 in Patients With Advanced Solid TumorsOscotec Inc.
- RECRUITINGPHASE3NCT06686771Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung CancerCanadian Cancer Trials Group
- RECRUITINGPHASE3NCT07251582Effect of Infusion Timing on Pathologic Response to Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung CancerHunan Province Tumor Hospital
See all trials for NON RARE IN EUROPE: Non-small cell lung cancer →